ライフサイエンスコーパス: dominant-negative

1 unctionally null or hypomorphic, while 1 was dominant negative.

2 3-3s by the pan-14-3-3 inhibitor difopein or dominant-negative 14-3-3theta further reduced neurite le

3 Dominant-negative Aalpha mutants retain binding to speci

4 val neuromuscular junction consistent with a dominant-negative action.

5 . elegans genetic complementation assays and dominant negative activities in mammalian systems, resul

6 ce truncated proteins that could either have dominant negative activities or cause loss of function a

7 The most common mutation, DNMT3A(R882H), has dominant negative activity that reduces DNA methylation

8 The resulting BCL11B protein had dominant negative activity, which abrogated the ability

9 ional activity of TAp63 and also impairs the dominant-negative activity of DeltaNp63, thereby control

10 evance of such effects (gain of function and dominant-negative activity) in lung adenocarcinoma are u

11 Recent reports have described a variety of dominant-negative AIRE mutations that likely contribute

12 Indeed, mice with a dominant-negative allele of Aire and deficiency in LYN s

13 Expression of a dominant-negative allele of MYC, termed OmoMYC, can indu

14 Tyr and p.Asn39Ser RAC1 variants function as dominant-negative alleles and result in microcephaly, re

15 exhibiting both overexpression of miR156 and dominant-negative alleles of SPL2 had reduced ASYMMETRIC

16 The TP53 mutations we observed are dominant negative and are the mutations most commonly se

17 Using mice expressing dominant negative and constitutively active Ampk in skel

18 r myc-LMX1BWT or myc-LMX1BR246Q, we observed dominant negative and haploinsufficiency effects of the

19 odels, cell lines, and ex vivo islets, using dominant negative and human- disease-allele point mutant

20 F) expressed in endothelial cells acted as a dominant negative and inhibited VE-cadherin gap formatio

21 Inhibition of these complexes by a dominant-negative approach led to impaired growth of a m

22 A dominant-negative approach to interfere with DsbA2 funct

23 Dominant negative Arf6 rescues this defect, suggesting t

24 s shown by knockdown and overexpression of a dominant-negative Arf6 mutant.

25 Cell-penetrating peptides combined with a dominant negative ATF5 cargo have recently shown efficac

26 cells with 3-methyladenine or overexpressing dominant-negative ATG5 abolished the deficiency of the p

27 n limits MAL glutathionylation and acts as a dominant negative, blocking the interaction of MAL with

28 in Cav1(-/-) MEFs, CAV1-P158 functions as a dominant negative by partially disrupting WT CAV1 traffi

29 small interfering RNA, or expression of the dominant-negative C-terminal domain.

30 we hypothesized that selective expression of dominant-negative C-terminus-truncated human DISC1 (muta

31 st using transient viral (HSV) expression of dominant-negative CaMKII-alpha (K42M) in the hippocampus

32 ty was reduced in neurons transfected with a dominant-negative cAMP response element binding protein

33 cannot bind to MT plus ends but can act in a dominant-negative capacity to reduce polymerization rate

34 AV1 was evident, whereas transduction with a dominant negative CAV1 mutated at tyrosine 14 reduced th

35 ic constriction, when compared with mock- or dominant-negative CCN1-infected control subjects, and im

36 ed in the disease tissues, whereas that of a dominant-negative CD40 isoform was decreased.

37 ater selectivity for Cdk5, and expression of dominant negative Cdk5 abolishes the ability of dbcAMP o

38 d ARCaPM prostate cancer cell models using a dominant-negative construct resulted in decreased tumor

39 Finally, expression of a dominant-negative construct that competes with EB3 bindi

40 orms were blocked by overexpressing specific dominant-negative constructs in either presynaptic or po

41 In vivo expression of a dominant-negative Cul1 enhances steady-state levels of C

42 s with only loss-of-function effects (mostly dominant-negative current amplitude reduction) in eight

43 Using a dominant negative D403E polymerase (Pol) III alpha that

44 Using a dominant-negative, deacetylase-dead point mutant virus (

45 phosphorylation, and therefore, TAR may be a dominant negative decoy molecule in cells.

46 Wild-Type and dominant-negative-DISC1 (DN-DISC1) mice were injected wi

47 In cells knocking down or overexpressing dominant negative (DN) forms of the components of ESCRT-

48 N-associated adaptor proteins and a panel of dominant negative (DN) Rab GTPases involved in TGN-endos

49 A dominant-negative (dn) atypical PKM selectively reversed

50 We found that overexpression of dominant-negative (DN) forms of NSF or knockdown of the

51 PRAS40 knockdown (KD) or PRAS40 dominant-negative (DN) mutant overexpression blocks not

52 CaMKIV signaling in individual neurons using dominant-negative (dn) or constitutively-active (ca) for

53 ss of function mechanism but also involves a dominant negative effect and/or toxic gain of function f

54 merization was indispensable for the strong, dominant negative effect of catalytically inactive PKDs.

55 of calnexin rescued wild-type GlyT2 from the dominant negative effect of the mutant, increasing the a

56 h a severe epileptic encephalopathy due to a dominant negative effect of the mutation, while heterozy

57 sion in gap junction channels, reverting the dominant negative effect of the p.Asp50Asn mutation.

58 erozygosity observed in patients, revealed a dominant negative effect of TRPC6 G757D.

59 Overexpression of S451A mutant had dominant negative effect on collagen biosynthesis; drast

60 sent B cells and was demonstrated to exert a dominant negative effect on T- and B-cell development in

61 eas the FLCN K508R mutant protein may have a dominant negative effect on the function of wild-type FL

62 ts in loss of function while also exerting a dominant negative effect on wild-type CARD11.

63 with the LMX1BR246Q mutation may be due to a dominant negative effect on WT1(-KTS) isoforms that may

64 s unclear; different models suggest either a dominant negative effect or haploinsufficiency.

65 ssense mutation in the ITGB4 gene exerting a dominant negative effect that cosegregates with the EB p

66 of calpain 3 on western blotting, suggest a dominant negative effect with a loss-of-function mechani

67 These assays revealed a dominant negative effect, reducing the activity of a con

68 significantly delayed sodium current with a dominant negative effect.

69 downstream targets AKT and ERK confirmed the dominant negative effect.

70 ploinsufficiency because they do not exert a dominant-negative effect in overexpression experiments.

71 ed fully functional in ndk5 cells elicited a dominant-negative effect in wild-type cells, causing par

72 36E coexpression only partially restores the dominant-negative effect of EA2 mutants on CaV2.1 WT fun

73 essential function could be abrogated by the dominant-negative effect of HOXD10 as shown by a genetic

74 d, suggesting muscle dysfunction is due to a dominant-negative effect of mutant protein on muscle con

75 ransfected with control CSF2RB, indicating a dominant-negative effect of the mutant gene.

76 Cell transfection studies demonstrated a dominant-negative effect of the p.His257Arg mutation on

77 tant with deletion of the D-box region had a dominant-negative effect on androgen-dependent growth of

78 ponsible for the interaction with E2F1 has a dominant-negative effect on BRCA1 expression and HR by s

79 main (ECD) of Il-1Rrp2 or IL-1RAcP exhibited dominant-negative effect on IL-36R signaling.

80 o provoke such events, and instead exerted a dominant-negative effect on MAPK activation and cell mig

81 f E2 approximately Ub and thus a concomitant dominant-negative effect on other E3s in vitro, raising

82 a de novo truncation mutation resulting in a dominant-negative effect that is associated with juvenil

83 of the carboxy-terminus of the protein has a dominant-negative effect, causing mitochondrial dysfunct

84 es that these variants are likely to exert a dominant-negative effect, given that both alleles are ex

85 n S. cerevisiae, there was no evidence for a dominant-negative effect.

86 1.2 channels showed loss of function with a dominant-negative effect.

87 ary HLH by contributing to HLH via a partial dominant-negative effect.

88 zebrafish embryos, suggesting that they have dominant-negative effect.

89 ing the Sin3-like domain, which could have a dominant-negative effect.

90 wild-type or mutant H3.3 alleles and showed dominant negative effects of H3.3R26 and H3.3K27 in modu

91 ressor 1 (NCOR1) was reported to mediate the dominant negative effects of mutated TRalpha1.

92 in vitro, we tested the hypothesis that the dominant negative effects of the mutated proteins are du

93 single 307Gln-270His haplotype that confers dominant negative effects on P2X7 function and protectio

94 eins, Su(H)(S269D) and Su(H)(R266H) provoked dominant negative effects upon overexpression.

95 ly dead PP1 mutant does not rescue and shows dominant negative effects.

96 The H92P mutation mimics the dominant-negative effects of the C91A mutation, presumab

97 Our findings rule out dominant-negative effects of the mutation.

98 EA2-causing mutants may exert dominant-negative effects on the CaV2.1 wild-type subuni

99 s-of-function (LOF) mutations that can exert dominant-negative effects.

100 he multivesicular body (MVB) pathway using a dominant negative ESCRT (endosomal sorting complexes req

101 fsX478, and R433fsX502) that functioned in a dominant negative fashion.

102 on, decrease transcriptional repression in a dominant-negative fashion and impair hematopoiesis.

103 Some mutated spastins may act in dominant-negative fashion to lower microtubule-severing

104 stone lysine acetyltransferase activity in a dominant-negative fashion, with concomitant global reduc

105 demonstrate preferential elimination of the dominant-negative FGFR3 c.1138G>A allele in fibroblasts

106 0S connexin 43 (Cx43) mutant protein that is dominant negative for Cx43 protein production of <50% of

107 uces a gain of function that gives rise to a dominant negative form of CAV1, defining a new mechanism

108 When Jurkat cells expressing a dominant negative form of NDE1 (NDE1-enhanced GFP fusion

109 ese drugs is eliminated in mice expressing a dominant negative form of NR4A and attenuated in mice wi

110 ell-intrinsic PD-1 blockade strategy using a dominant negative form of PD-1.

111 In contrast, a virus that overexpressed a dominant-negative form of a 4.1N C-terminal domain (HSV

112 on did not occur in glial cells expressing a dominant-negative form of cGMP-dependent protein kinase

113 nt on PKA, and was completely abrogated by a dominant-negative form of CREB.

114 on of PLC-beta3 at least as effectively as a dominant-negative form of full-length PLC-beta3.

115 The introduction of the dominant-negative form of RAGE lacking RAGE signalling t

116 ne region of the ectodomain that generated a dominant-negative form of TLR9.

117 ession of luciferase together with Myc and a dominant-negative form of Trp53 revealed that GABAergic

118 RNAi knockdown or the targeted expression of dominant-negative forms of Ap or Chi in PDF-expressing n

119 clin-dependent kinases (CDKs), as well as by dominant-negative forms of CDK1 and CDK2 and the pan-CDK

120 nvestigations using constitutively active or dominant-negative forms of Rab GTPases provided addition

121 ated its global DNA-binding activity using a dominant-negative FOS peptide.

122 Conversely, a dominant negative Foxc1 inhibits the Ihh target gene exp

123 nant distal hereditary motor neuropathy of a dominant-negative frameshift mutation at the C-terminus

124 ely large effect size conferred by a partial dominant-negative function phenotype.

125 ncated proteins which might have residual or dominant negative functions.

126 in was secreted from cells, and behaved as a dominant-negative FZD5 receptor, antagonizing both canon

127 ses (60%) consisting of the highly recurrent dominant negative G17V variant in most cases and a novel

128 A dominant-negative Galpha chimera that interferes with Ga

129 B inhibitory peptide TAT-NBD or GAP43(S41A) (dominant-negative GAP43) or knockdown of GAP43 all inhib

130 type, constitutively active (GTP bound), or dominant-negative (GDP bound) rab17.

131 tudy, we used viral-mediated expression of a dominant-negative GluN1 subunit (HSV-dnGluN1) in VTA neu

132 A catalytically inactive dominant-negative GODZ construct significantly reduced H

133 Finally, dominant-negative GusR variants are validated in cell-ba

134 nhances cell survival, whereas expression of dominant negative HSF1 leads to enhanced TDP-43 aggregat

135 We tested this mechanism using a dominant-negative human Xrn2 mutant and found that it de

136 Mice expressing an endothelial-specific dominant negative IkappaBalpha cassette under the Tie2 p

137 lls could not suppress CD4(+) T cells with a dominant-negative IL-10R.

138 ecific transgenic animals expressing a SNARK dominant-negative inactive mutant (SDN) had increased my

139 MAP2K4, indicating these mutations impose a dominant-negative influence to promote growth (Figure 4F

140 Knockdown and dominant negative inhibition of Gnaz dampen the axon-rep

141 ation of human myogenic progenitors and that dominant negative inhibition of TCF4 prevents differenti

142 n but not the Rad50 binding domain acts as a dominant negative inhibitor of E2-dependent HPV replicat

143 ID4, a dominant-negative inhibitor of basic helix-loop-helix tr

144 is not sequestered by mutant NS1B acts as a dominant-negative inhibitor of oligomerization of the mo

145 eta-isoform of human GR (hGRbeta), acts as a dominant-negative inhibitor of the classic hGRalpha and

146 r induced expression of an isoform that is a dominant-negative inhibitor of wild-type ERG function.

147 somes, and that the Stx3-5R mutant acts as a dominant-negative inhibitor.

148 The G87R and R139W mutants behave as dominant-negative inhibitors of CaMKK2 signaling in cell

149 This study provides evidence for a conserved dominant-negative inhibitory role of histone K-to-M muta

150 o because OMPs that assemble slowly can form dominant-negative interactions with the Bam complex.

151 actor VIII, or collagen, causing VWD through dominant-negative intracellular retention of coexpressed

152 he adjuvant, an adenoviral vector encoding a dominant negative isoform of Src homology region 2 domai

153 Hedgehog signaling induced expression of a dominant negative isoform of TCF7L2 (dnTCF7L2) in interz

154 both the nucleus and cytoplasm, acting as a dominant negative isoform to YAP activity.

155 diabetes (T1D), Deaf1 is spliced to form the dominant-negative isoform Deaf1-Var1.

156 The Pbx1-d dominant-negative isoform is more frequent in CD4(+) T c

157 ted knockdown of PKCdelta or expression of a dominant-negative isoform restored insulin signaling of

158 ediated endocytosis, expression of a dynamin dominant-negative K44A mutant also blocked activated PAR

159 B knockout or viral-mediated expression of a dominant negative, kinase-dead TrkB mutant.

160 Using dominant-positive (LdSar1:H74L) and dominant-negative (LdSar1:T34N) mutants of LdSar1, we fo

161 ted patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killi

162 at position R882 have been shown to cause a dominant negative loss of DNMT3A methylation activity, b

163 utations in the gene KCNA2, causing either a dominant-negative loss-of-function or a gain-of-function

164 of-function MAFB mutations causing DRS and a dominant-negative MAFB mutation causing DRS and deafness

165 model in which the mutant protein acts in a dominant negative manner on the WT BRCA1, impairing the

166 y affects MRE11 foci formation and acts in a dominant negative manner to prevent long-range resection

167 nhibited G-CSF-induced expression of NE in a dominant negative manner.

168 e function of the wild-type FEN1 enzyme in a dominant-negative manner and impairs long-patch base exc

169 e discovered that Aalpha mutants behave in a dominant-negative manner due to gain-of-function interac

170 ne 3 Lys-36 to Met mutation (K36M) acts in a dominant-negative manner to cause global reduction of H3

171 produces a truncated protein that acts in a dominant-negative manner to prevent full-length MAGI3 fr

172 ation, and that the mutated kinase acts in a dominant-negative manner to reduce CaMKIIalpha-WT autoph

173 ry effect of phosphorylation on MR acts in a dominant-negative manner, effectively amplifying its fun

174 ene expression driven by wild-type AIRE in a dominant-negative manner, unlike CARD or truncated AIRE

175 ADAMTS activity, in vitro and in vivo, in a dominant-negative manner.

176 cted mice expressing the pan-Notch inhibitor dominant negative mastermind-like within mature T cells

177 cific expression of the pan-Notch inhibitor, dominant-negative Mastermind (DNMAML).

178 is were confirmed by gene sequencing to bear dominant-negative MC1R mutations.

179 .12] vs 0.44 [0.05]; P < .001), suggesting a dominant negative mechanism for the mutation.

180 This analysis supports a dominant-negative mechanism for GS variants in ITPR1.

181 The genetic analysis favors a predominantly dominant-negative mechanism for the action of amino acid

182 the p.Arg528Trp variant functions through a dominant-negative mechanism that results in small mitoch

183 HI) mechanisms, such as gain-of-function and dominant-negative mechanisms, are often characterized by

184 ndent increase in fibre size is prevented by dominant negative MEF2, while constitutively active MEF2

185 HSP proteins was combined with expression of dominant-negative microtubule regulators, suggesting tha

186 fferent (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and th

187 ne receptor alpha (THRA) gene mutations, via dominant negative mode, cause erythroid abnormalities in

188 Expression of dominant negative mutant HNF-1beta or kidney-specific in

189 , we overexpressed beta-arrestin2-(1-320), a dominant negative mutant known to block receptor endocyt

190 Overexpression of a dominant negative mutant of EhRab35 reduced phagocytic c

191 and functional role of omega, we isolated a dominant negative mutant of omega (omega6), which is pre

192 of Rab1), and GFP-LdRab1:S22N (a GDP-locked dominant negative mutant of Rab1).

193 -Cys (DHHC) zinc finger protein; (ii) a GODZ dominant-negative mutant and an inhibitor of palmitoylat

194 By using cell lines stably expressing a dominant-negative mutant form of VPS4, we also show that

195 ting recruitment of Vinculin by expressing a dominant-negative mutant increases the rate of furrow in

196 n of PKMzeta in mPFC by expressing a PKMzeta dominant-negative mutant induced depressive-like behavio

197 Using Rac1-specific inhibitor and dominant-negative mutant N17Rac1, here we demonstrate th

198 Expressing a dominant-negative mutant of NF-YA, a key transcriptional

199 and NF-kappaB, as well as transfection of a dominant-negative mutant of Ras (RasN17), significantly

200 differentiation by targeting expression of a dominant-negative mutant of retinoic acid receptor alpha

201 se observations suggest that D477G acts as a dominant-negative mutant of RPE65 that delays chromophor

202 Consistent with this effect, expressing a dominant-negative mutant of ULK1 or ATG4b or a ULK1-targ

203 interaction of UL20 with GODZ, using a GODZ dominant-negative mutant or possibly GODZ shRNA, should

204 Using a dominant-negative mutant protein of the methyl-directed

205 Moreover, expression of dominant-negative mutant Syt1 which inhibits Ca(2+)-depe

206 Analysis of dominant negative mutants is consistent with dimerizatio

207 ologs in a yeast model host or expression of dominant negative mutants of plant Rab5 greatly decrease

208 and were prevented by TRPC1, -C4, and Orai1 dominant negative mutants or TRPC5 siRNA.

209 olerance in HSFA6b-null, overexpression, and dominant negative mutants revealed that HSFA6b is a posi

210 -positive (LdRab5a:Q93L and LdRab5b:Q80L) or dominant-negative mutants (LdRab5a:N146I and LdRab5b:N13

211 Here, we show that dominant-negative mutants of ATL1 in PC-12 cells inhibit

212 Dominant-negative mutants of PAX5 and IKZF1, however, re

213 Using inhibitors and dominant-negative mutants, we found that eIF4A is requir

214 how that the mutant phenotype is caused by a dominant-negative mutation in an actin gene.

215 Consequently, KI mice with dominant negative mutations had much less wild-type rece

216 dities resulting from haploinsufficiency and dominant negative mutations, however, have not been comp

217 tural change induced by known recessive- and dominant-negative mutations in other disease-associated

218 nt hyper-IgE syndrome (AD-HIES) is caused by dominant-negative mutations in STAT3; however, the molec

219 pressed hTACI A181E and mTACI A144E acted as dominant-negative mutations in transfectants, homozygosi

220 nct mutations in the kinase domain behave as dominant-negative mutations in zebrafish over-expression

221 a rare autosomal dominant disorder caused by dominant-negative mutations within the KRT3 or KRT12 gen

222 owing the discovery of two patients carrying dominant-negative mutations.

223 ac1 using either small molecule inhibitor or dominant-negative N17Rac1 abrogates clonogenic survival

224 creased amount of normal fibrillin-1, or (2) dominant negative, normal fibrillin-1 abundance with mut

225 omoter activity, whereas the introduction of dominant-negative NRF-1 repressed such activity.

226 gg1 O-GlcNAcylation in vivo by introducing a dominant negative O-GlcNAc transferase mutant (F460A) re

227 interactions by genetic deletion of a short, dominant negative of Homer, H1a, rescues many phenotypes

228 e show that XBP1(U) functions beyond being a dominant negative of XBP1(S).

229 The remaining mutations are probably weakly dominant negative or their effects are context dependent

230 Overexpression of a PK4 dominant-negative or pharmacological inhibition of PK4 b

231 nated by either BTP2 or by coexpression of a dominant negative Orai construct.

232 Expression of dominant-negative Orai in dopaminergic neurons of pupae

233 Transgenic mice expressing a dominant-negative Orai1 mutant (E108Q) increases albumin

234 itor SB202190, and kinase-dead [p38(KD)] and dominant-negative [p38(DN)] forms of p38alpha.

235 A by endothelial cell-specific expression of dominant-negative PKA in mice led to perturbed vascular

236 wn-regulation of PKAc1 or stabilisation of a dominant-negative PKAr isoform that does not bind cAMP t

237 t UL20 is palmitoylated by GODZ using a GODZ dominant-negative plasmid.

238 levels and almost completely eliminated by a dominant-negative PLCdelta1 mutant and a constitutively

239 Expression of dominant-negative PPAR-delta in the central nervous syst

240 Expression of dominant-negative PPAR-delta specifically in the striatu

241 The S348A/S409A mutant of LARP6 acts as a dominant negative protein in collagen biosynthesis, whic

242 ysis of PKCiota wild-type, catalytic active, dominant-negative protein isoforms strengthened the asso

243 tigating Rab11 function by overexpression of dominant negative Rab11 impaired NET function.

244 Overexpression of dominant-negative Rab11 and RNA interference knockdown o

245 defective trafficking in cystinosis, whereas dominant-negative Rab11 or Rab7 impaired LAMP2A traffick

246 ate that Munc13-4 binds to Rab11a but not to dominant negative Rab11a.

247 en fluorescent protein (GFP)-tagged Rab14 or dominant negative Rab14, or with small interfering RNA (

248 more, knockdown of Rab35 and expression of a dominant-negative Rab35 mutant both inhibited histamine-

249 Moreover, expression of a dominant-negative Rab5 construct markedly reduced APP-in

250 ced atrophy of BFCNs that was rescued by the dominant-negative Rab5 mutant, Rab5S34N.

251 l blockade of both pathways by Atg5(-/-) and dominant-negative rab5, ER cholesterol fails to increase

252 eltatailpiece, as well the overexpression of dominant negative Rab6a(T27N), preserved a compact Golgi

253 Similar effects were observed when a dominant-negative Rab9 mutant (Rab9-GDP) was employed.

254 ng Rac1 signaling by RNAi, expression of the dominant-negative Rac1 (Rac1 DN), or the specific Rac1 i

255 Cs with the EGF receptor inhibitor AG1478, a dominant-negative RAS, an Src homology 2 domain-containi

256 t the heterozygous mutations in L-ORD show a dominant negative, rather than a haploinsufficient, dise

257 ell-intrinsic PD-1 shRNA blockade, or a PD-1 dominant negative receptor, restored the effector functi

258 astly, we show that TLR9(471-1032) is also a dominant-negative regulator of TLR9 signaling.

259 yL1 and Ahcy89E/CG8956/dAhcyL2, which act as dominant-negative regulators of canonical AHCY.

260 Rather than being dominant-negative regulators, Tcf1 short isoforms are ad

261 HS-R1b) has been suggested to simply exert a dominant negative role in the trafficking and signaling

262 l transition and, contrary to their proposed dominant-negative role, did not interfere with the expre

263 s, knockdown of Rusc1 or overexpression of a dominant-negative Rusc enhances Hh signaling during eye

264 6S variant suggest both loss of function and dominant-negative sequestration of wild-type protein.

265 Intriguingly, DiRas1 acts similarly to a dominant-negative small GTPase, binding to SmgGDS and in

266 Finally, overexpression of a dominant-negative Snail1 homolog in zebrafish elevated t

267 Lysine-Specific Demethylase 1 (LSD1) and its dominant-negative splicing isoform neuroLSD1, in the mod

268 Individuals with dominant-negative STAT3 mutations (STAT3(mut) ) or a los

269 using a novel hypoxia-dependent, reversible dominant-negative strategy to regulate autophagy at the

270 nhibitor compound C or adenovirus expressing dominant-negative subunits of AMPK increased cue-induced

271 We report 1) that hERG1a dominant-negative subunits suppress hERG1b currents (and

272 thers may be caused by loss-of-function plus dominant negative suppression and other cellular toxicit

273 ic reticulum-associated protein degradation, dominant negative suppression of partnering subunits, mu

274 ceptor channel function and the differential dominant negative suppression, as well to toxicity relat

275 exhibit impaired protein stability and exert dominant-negative suppression of CaV2.1 wild-type (WT) p

276 expression) or loss-of-function experiments (dominant negative TCF4).

277 Here, we describe a designed dominant negative termed A-ZIP53 that has a glutamic aci

278 osterior left atrium of plasmid expressing a dominant-negative TGF-beta type II receptor (pUBc-TGFbet

279 DCC-EGFP with DCC-T-mCherry, a putative DCC dominant negative that replaces the DCC intracellular do

280 By expression of a dominant-negative TNF peptide via lentiviral vector inje

281 that the engineered monomer functioned as a dominant negative to inhibit TGF-beta signaling with a K

282 wild-type PANX1 suggested the mutant was not dominant-negative to PANX1 channel function.

283 Despite inhibition by dominant-negative TonEBP, IL6 and NOS2 promoters were no

284 in MDCK monolayers led to the proposal of a dominant-negative trafficking mechanism to explain AE1-a

285 Using mice expressing a dominant negative TRalpha1 mutant (TRalpha1PV; Thra1 (PV

286 Inclusion of dominant-negative transcription factor 4 at the time of

287 K2 expression and negatively correlated with dominant-negative truncated NTRK2 level.

288 siRNA-mediated depletion or expression of a dominant-negative truncation that models the chromosomal

289 members, resulting in expression of the TP53 dominant negative truncations DeltaNTrp63 and DeltaNTrp7

290 e hypothesized that gene-based expression of dominant-negative type II TGF-beta receptor (TGF-beta-RI

291 ds to inhibit unc-9-based gap junctions with dominant-negative unc-1 transgenes.

292 We exploited a genetic selection using a dominant negative variant of the polymerase catalytic su

293 hich are the cognate mutants to Ras(S17N), a dominant-negative variant of Ras that displays decreased

294 of the suppressing DNAs encoded a truncated dominant-negative variant of the 26S proteasome subunit,

295 Here, we demonstrate that oncogenic DNp73, a dominant-negative variant of the tumor-suppressor p73, c

296 ants, we generated fish expressing inducible dominant negative Vegfaa.

297 mimic monopolar spindle defects induced by a dominant negative version of this kinase.

298 tion of TPL activity induced by expressing a dominant negative version of TPL (tpl-1) in phloem compa

299 Here, we show that overexpression of a dominant-negative version of DA1 enhances leaf size in a

300 Dual expression of dominant-negative versions of Arabidopsis homologs of Vp